Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Gastrointestinal Cancer Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

 
Rui-hua Xu, Huiyan Luo, Jin Lu, et al.
The study authors conclude that Addition of camrelizumab to chemotherapy provided superior overall and progression-free survival versus placebo plus chemotherapy, with a manageable safety profile. The authors state, that Camrelizumab in combination with paclitaxel and cisplatin has the potential to become a new standard 1-line therapy in patients with advanced or metastatic ESCC. Clinical trial information: NCT03691090
 
 
Ian Chau, Yuichiro Doki, Jaffer A. Ajani, et al.
The study authors conclude that nivolumab (NIVO) plus chemo and NIVO plus ipilimumab both demonstrated superior overall survival versus chemotherapy. Durable objective responses and acceptable safety were observed in patients with advanced ESCC. Each combination represents a potential new 1st-line treatment option. Clinical trial information: NCT03143153
 
 
Markus H. Moehler, Kohei Shitara, Marcelo Garrido, et al.
The study authors conclude that adding nivolumab (NIVO) to chemotherapy demonstrated improved overall and progression-free survival benefits in all randomized patients. An acceptable safety profile and maintained tolerability, as well as QoL, were observed. According to the authors, this provides further support for NIVO + chemotherapy as a standard 1st-line treatment for advanced GC/GEJC/EAC. Clinical trial information: NCT02872116
 
 
Ronan Joseph Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, et al.
The study authors conclude that adjuvant nivolumab showed a clinically meaningful efficacy together with an acceptable safety profile, and maintained QoL. According to the authors, this provides further support for its use as a new standard of care for patients with resected EC/GEJC who received neoadjuvant chemoradiotherapy with residual pathologic disease. Clinical trial information: NCT02743494
 
 
John V. Reynolds, Shaun R. Preston, Brian O'Neill, et al.
The study authors conclude that the trial reveals no evidence that perioperative chemotherapy is unacceptably inferior to multimodal therapy, notwithstanding greater proxy markers of local tumour response in the CROSS arm (carboplatin/paclitaxel, 41.4Gy radiation therapy). Oncologic and operative outcomes were consistent with optimum modern benchmarks. The author's data strongly suggest non-inferiority. This supports equipoise in decision-making in modern practice. Clinical trial information: NCT01726452
 
 
Manish A. Shah, Khaldoun Almhanna, Syma Iqbal, et al.
The study authors conclude that adding pembrolizumab to preoperative chemoradiotherapy for esophageal adenocarcinoma is safe and associated with a significantly higher MPR rate compared to historical data. They found major pathologic response to be significantly enriched in EAC/GEJ type I tumors compared with GEJ II/III. This was  associated with important differences in the baseline tumor immune microenvironment. Clinical trial information: NCT02998268
 
 
Changhoon Yoo, Kyu-Pyo Kim, Ilhwan Kim, et al.
The study authors conclude that Nal-IRI plus 5-FU/LV significantly improved overall and progression-free survival compared to 5-FU/LV in biliary tract cancer patients who progressed on prior GemCis. The authors state, that Nal-IRI plus 5-FU/LV should be considered as standard 2nd-line therapy for advanced biliary tract cancer. Clinical trial information: NCT03524508
 
 
Ning Lyu, Ming Zhao;
The study authors conclude that their study proved that HAIC-FO had superior efficacy and survival outcome than sorafenib in the 1st-line treatment of primary diagnostic, advanced HCC. This indicates, that for patients with heavy intrahepatic tumor burden, HAIC-FO monotherapy might be a better strategy than sorafenib. Clinical trial information: NCT03164382
 
Shaohua Li, Chong Zhong, Qiang Li, Jingwen Zou, et al.
The study authors conclude that neoadjuvant TAI before hepatectomy may bring survival benefits for resectable Barcelona Clinic Liver Cancer (BCLC) stage A/B HCC patients beyond Milan criteria. Trial number: NCT03851913. Clinical trial information: NCT03851913